ADC Therapeutics SA Increase Decrease Through Transactions With Owners
Discontinued › Notes
ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners · last filed 2023-11-07
- ADC Therapeutics SA increase decrease through transactions with owners for the quarter ending 2023-09-30 was $2.43M, a 94.00% decline year-over-year.
- ADC Therapeutics SA increase decrease through transactions with owners for the quarter ending 2023-06-30 was $1.12M, a 91.91% decline year-over-year.
- ADC Therapeutics SA increase decrease through transactions with owners for the quarter ending 2023-03-31 was $8.50M, a 36.57% decline year-over-year.
- ADC Therapeutics SA increase decrease through transactions with owners for the quarter ending 2022-12-31 was $7.52M, a 45.23% decline year-over-year.
| Period end | Increase Decrease Through Transactions With Owners 3 month | Increase Decrease Through Transactions With Owners 6 month | Increase Decrease Through Transactions With Owners 9 month | Increase Decrease Through Transactions With Owners 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.43M 6-K · filed 2023-11-07 | $3.55M derived: sum of 2 quarters · filed 2023-11-07 | $12.05M 6-K · filed 2023-11-07 | $19.57M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $1.12M 6-K · filed 2023-08-08 | $9.62M 6-K · filed 2023-08-08 | $17.14M derived: sum of 3 quarters · filed 2023-08-08 | $57.66M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $8.50M 6-K · filed 2023-05-09 | $16.02M derived: sum of 2 quarters · filed 2023-05-09 | $56.55M derived: sum of 3 quarters · filed 2023-11-07 | $70.36M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $7.52M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $48.05M derived: sum of 2 quarters · filed 2023-11-07 | $61.87M derived: sum of 3 quarters · filed 2023-11-07 | $75.26M 20-F · filed 2023-03-15 |
| 2022-09-30 | $40.53M 6-K · filed 2023-11-07 | $54.35M derived: sum of 2 quarters · filed 2023-11-07 | $67.75M 6-K · filed 2023-11-07 | $81.47M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $13.82M 6-K · filed 2023-08-08 | $27.22M 6-K · filed 2023-08-08 | $40.94M derived: sum of 3 quarters · filed 2023-08-08 | $56.02M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $13.40M 6-K · filed 2023-05-09 | $27.12M derived: sum of 2 quarters · filed 2023-05-09 | $42.20M derived: sum of 3 quarters · filed 2023-05-09 | $60.70M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $13.73M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $28.80M derived: sum of 2 quarters · filed 2023-03-15 | $47.30M derived: sum of 3 quarters · filed 2023-03-15 | $61.26M 20-F · filed 2023-03-15 |
| 2021-09-30 | $15.08M 6-K · filed 2022-11-08 | $33.58M derived: sum of 2 quarters · filed 2022-11-08 | $47.53M 6-K · filed 2022-11-08 | $62.97M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $18.50M 6-K · filed 2022-08-09 | $32.45M 6-K · filed 2022-08-09 | $47.89M derived: sum of 3 quarters · filed 2023-03-15 | $247.83M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $13.95M 6-K · filed 2022-05-09 | $29.39M derived: sum of 2 quarters · filed 2023-03-15 | $229.33M derived: sum of 3 quarters · filed 2023-03-15 | $480.93M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $15.44M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $215.37M derived: sum of 2 quarters · filed 2023-03-15 | $466.98M derived: sum of 3 quarters · filed 2023-03-15 | $470.77M 20-F · filed 2023-03-15 |
| 2020-09-30 | $199.93M 6-K · filed 2021-11-02 | $451.54M derived: sum of 2 quarters · filed 2021-11-02 | $455.33M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $251.60M 6-K · filed 2021-08-03 | $255.39M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $3.79M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $102.63M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $445.00K 20-F · filed 2021-03-18 |